Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.14.86.75
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Gastroenterology
Oncology

Endoscopic treatment for gastric GIST possible for select cases

Posted on

Endoscopic treatment is feasible in certain patients with gastrointestinal stromal tumors (GISTs), according to a study, however further treatment may be needed if pathology reports indicate intermediate- or high-risk groups.

In this retrospective study, outcomes from 135 gastric subepithelial tumors (SETs) resected by endoscopic procedures and confirmed as GISTs by histopathology were analyzed.

-Advertisement-
-Advertisement-

Tumors were in the body (43%), fundus (26.7%), and cardia (17%) and resected by endoscopic submucosal dissection (85.2%), endoscopic mucosal resection (6.7%), submucosal tunneling endoscopic resection (5.9%), and endoscopic full-thickness resection (2.2%). Macroperforation and microperforation occurred in 4.4% and 6.7% of cases, respectively.

The R0 resection rate was 15.6%, however, the complete resection rate by endoscopic view was 90.4%. Of the 90.4%, 54.8% of cases were in the very-low-risk group, 28.1% in the low-risk group, 11.9% in the intermediate-risk group, and 5.2% in the high-risk group.

Of the 118 patients who were monitored for >6 months, recurrence was found in 3.4% during the 36.5 months of follow-up

Reference
Joo MK, Park JJ, Lee YH, et al. Clinical Efficacy and Safety of Endoscopic Treatment of Gastrointestinal Stromal Tumors in the Stomach. Gut Liver. 2023 Feb 15. doi: 10.5009/gnl210454. Epub ahead of print. PMID: 36789572.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-